ABBV - Abbvie Inc Stock Analysis
Abbvie Inc (ABBV) is a publicly traded company listed on the Mega. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 402.35B, generates annual revenue of 62.82B, and reports net income of 3.60B. As of the latest data, the stock is trading at 227.73 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. The stock offers a moderate dividend yield (3.0%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.0), indicating current market sentiment. Institutional ownership is reported at 76.15%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 18.35%, trading within a 52-week range of 181.73 - 244.81.
ABBV - Abbvie Inc
227.73
Analyst Consensus
Buy 4.0
ABBV – Analyst Rating Summary
- Strong Buy: 9
- Buy: 22
- Hold: 9
- Sell: 0
- Strong Sell: 0
- Total Analysts: 40
| Index: | S&P 500 | P/E: | 112.32 | EPS (ttm): | 2.03 | Insider Own: | 0.12% | Shs Outstand: | 1.77B | Perf Week: | 0.22% |
| Market Cap: | 402.35B | Forward P/E: | 13.98 | EPS next Y: | 16.29 | Insider Trans: | -2.14% | Shs Float: | 1.76B | Perf Month: | 9.22% |
| Income(ttm): | 3.60B | PEG: | 0.65 | EPS next Q: | 3.76 | Inst Own: | 76.15% | Short Float: | 1.31% | Perf Quarter: | 3.66% |
| Revenue(ttm): | 62.82B | P/S: | 6.40 | EPS this Y: | 42.67% | Inst Trans: | -0.25% | Short Ratio: | 3.58 | Perf Half Y: | 1.13% |
| Book/sh: | -3.77 | P/B: | - | EPS next Y: | 14.15% | ROA: | 2.64% | Short Interest: | 23.16M | Perf Year: | 18.35% |
| Cash/sh: | 5.32 | P/C: | 42.84 | EPS next 5Y: | 21.56% | ROE: | 15221.82% | 52W Range: | 181.73 - 244.81 | Perf YTD: | -0.33% |
| Dividend Est.: | 6.84 (3.00%) | P/FCF: | 20.14 | EPS past 3/5Y: | -29.11% -2.81% | ROIC: | 6.21% | 52W High: | 244.81 -6.98% | Beta: | 0.30 |
| Dividend TTM: | 6.74 (2.96%) | Quick Ratio: | 0.68 | Sales past 3/5Y: | 1.75% 5.95% | Gross Margin: | 70.58% | 52W Low: | 181.73 25.31% | Perf 5Y: | 97.31% |
| Dividend Ex-Date: | Apr 15, 2026 | Current Ratio: | 0.80 | EPS Y/Y TTM: | -13.63% | Oper. Margin: | 33.58% | RSI (14): | 66.02 | Volatility: | 2.11% 2.32% |
| Employees: | 57000 | Debt/Eq: | - | Sales Y/Y TTM: | 9.50% | Profit Margin: | 5.72% | Recom: | 1.67 | Target Price: | 253.85 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | - | EPS Q/Q: | -46.38% | Payout: | 281.66% | Rel Volume: | 0.63 | Prev Close: | 224.77 |
| Sales Surprise: | 1.93% | EPS Surprise: | 2.23% | Sales Q/Q: | 12.43% | Earnings: | Apr 29 BMO | Avg Volume: | 6.47M | Price: | 227.73 |
| SMA20: | 4.36% | SMA50: | 8.03% | SMA200: | 3.35% | Undervalued: 11.47% | Volume: | 4,052,856 | Change: | 1.32% | |
Graham Classic formula value: 94.1
(P/E=8 * 1g) Min value: 53.88
(current P/E * 2g) Max value: 283.34
Average value: 143.77
About Abbvie Inc
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson's disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.